Regulation of the gene expression of Stromelysin-1 (matrix metalloproteinase-3), a member of the matrix metalloproteinase family, is critical for tissue homeostasis. The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic headto-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. Patterns of increased co-expression of Stromelysin-1 and Ets-1 genes have been observed in pathological processes such as rheumatoid arthritis, glomerulonephritis and tumor invasion. In this context, we show in a synovial fibroblastic model cell line (HIG-82), which is able to co-express Stromelysin-1 and Ets-1, that the EBS palindrome is essential for the expression of Stromelysin-1. More precisely, using electrophoretic mobility shift assays, DNA affinity purification and chromatin immunoprecipitation, we demonstrate that endogenous Ets-1, but not Ets-2, is present on this palindrome. The use of a dominant-negative form of Ets-1 and the decrease of Ets-1 amount either by fumagillin, an antiangiogenic compound, or by short interfering RNA show that the activation rate of the promoter and the expression of Stromelysin-1 correlate with the level of endogenous Ets-1. Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome.
Introduction
Stromelysin-1 or matrix metalloproteinase-3 (MMP-3) is a MMP characterized by a wide spectrum of substrates. It is involved in extracellular matrix remodeling during physiological processes such as morphogenesis, growth and wound repair (Sternlicht and Werb, 1999; Vu and Werb, 2000) . However, when misregulated, its expression is associated with erosive processes such as rheumatoid and osteoarthritis (Malemud and Goldberg, 1999) or invasive pathologies such as tumor growth and metastasis (Nelson et al., 2000; Zucker et al., 2000) . Furthermore, Stromelysin-1 was demonstrated to act as a mammary carcinogenesis promoter in a mouse model . In this context, Stromelysin-1 was recently reported to lead to genomic instability and epithelial-mesenchymal transition, owing to the induction of Rac 1b expression which causes an increase in cellular reactive oxygen species (Radisky et al., 2005) . It follows that a tight regulation of its gene expression is critical for cell and tissue homeostasis. Stromelysin-1 expression is mainly controlled at the transcription level. The importance of this regulation has been exemplified by the association of a common single-nucleotide polymorphism present in the Stromelysin-1 promoter, altering its activity, with the evolution of cancerous (Ghilardi et al., 2002) , cardiovascular (Terashima et al., 1999) and arthritic (Constantin et al., 2002) diseases. Among the specific DNA elements present in the Stromelysin-1 promoter (Ye et al., 1999; Rekdal et al., 2000) , an inverted tandem of Ets binding sites (EBS) spaced by four base pairs and located at À216/À201 (Figure 1a ) was found to be required for basal and phorbol 12-myristate 13-acetate (PMA)- (Buttice and Kurkinen, 1993) , platelet-derived growth factor (PDGF)- (Kirstein et al., 1996) or interleukin-1b (IL-1b)-induced expression (Quinones et al., 1994) .
EBS are B9-bp sequences centered over a purine-rich 5 0 -GGAA/T-3 0 core motif bound by Ets proteins, important transcription factors involved in development and in several types of cancer and other human diseases (Dittmer and Nordheim, 1998; Maroulakou and Bowe, 2000; Trojanowska, 2000; Oikawa and Yamada, 2003) . Several Ets proteins are able to stimulate the Stromelysin-1 promoter through this EBS palindrome: Ets-1 (Wasylyk et al., 1991) , Ets-2 ( Buttice and Kurkinen, 1993) and Pea-3 (Higashino et al., 1995) . Interestingly, all these Ets proteins have their DNA-binding activity downregulated by an intramolecular mechanism named autoinhibition (Pufall and Graves, 2002) . In the case of Ets-1, we showed that the presence of such an EBS tandem enables two Ets-1 molecules to overcome their autoinhibition. The two molecules bind to DNA cooperatively by a mechanism involving the exon VII-encoded domain of the protein (Baillat et al., 2002) . A similar binding cooperativity was observed with Ets-2. The elucidation of this binding mechanism led to the idea that such EBS palindromes could serve as specific response elements for autoinhibited Ets proteins such as Ets-1 or Ets-2. There is a strong presumption that transcriptional misregulation of Stromelysin-1 could be mediated by Ets-1. Indeed, on the one hand, the same proinflammatory cytokines as IL-1b and tumor necrosis factor (TNFa) are able to activate both Stromelysin-1 and Ets-1 (Mauviel, 1993; Redlich et al., 2001) , and on the other hand, patterns of increased coexpression of both genes have been documented in processes such as rheumatoid arthritis (Sun and Yokota, 2001) , glomerulonephritis (Naito et al., 2000) , angiogenesis (Sato et al., 2000) and tumor invasion (Wernert et al., 1994) . It is all the more important that Ets-1, among all the other Ets proteins, is considered as an independent marker of poor prognosis in various cancer types (Span et al., 2002; Mukherjee et al., 2003; Tokuhara et al., 2003) .
In this context, we focused on the implication of endogenous Ets-1 in the regulation of Stromelysin-1 expression. We used the HIG-82 synovial fibroblastic cell line described as a good model for first stages of rheumatoid arthropathy and for early stages towards malignancy (Lin et al., 1996) . The main reason to use these cells is their ability to co-express high amounts of Stromelysin-1 and Ets-1. Our study shows, for the first time, that endogenous Ets-1 is an actual regulator of Stromelysin-1 expression through its effective binding to the head-to-head EBS palindrome.
Results
Status of the Stromelysin-1 promoter and Ets-1 protein in HIG-82 cells HIG-82 cells are rabbit synovial fibroblastic cells described to respond to PMA or IL-1b, and consequently express various MMPs including Stromelysin-1 (Georgescu et al., 1988) . In this cellular context, we tested the activity of the Stromelysin-1 promoter regarding the integrity of the À216/À201 EBS tandem ( Figure 1a ). Transient transfections experiments were carried out in HIG-82 cells with luciferase reporter constructs containing either wild-type (WT) or EBS tandem mutants (see Figure 1b for details). Normalized activities showed that mutation of one (M1 and M2 mutants) or both (M1M2 mutant) EBS greatly affects the activity of the promoter (Figure 2a ). Similar behavior is observed in the case of the activation of the Stromelysin-1 promoter in response to Ets-1 or Ets-2 overexpression (Buttice and Kurkinen, 1993; Baillat et al., 2002) . This suggests that these proteins, able to bind cooperatively to the EBS tandem of the Stromelysin-1 promoter (Baillat et al., 2002) in contrast to other members of the ETS family (Hodge et al., 1996) , may play an important role in the activity of the Stromelysin-1 promoter in these cells. Furthermore, such EBS tandems are involved in the transcriptional response to various stimuli such as IL-1b (Kirstein et al., 1996) , PMA (Buttice and Kurkinen, 1993) and Ras activation (Galang et al., 1994) . In HIG-82 cells, consistent with their described phenotype, IL-1b and PMA treatment resulted in Stromelysin-1 protein secretion into the culture supernatant (Figure 2b ). The size of the detected protein (57 kDa) corresponds to the molecular weight of pro-Stromelysin-1. Interestingly, these treatments concomitantly resulted in a substantial increase of the p51 Ets-1 full-length isoform but not Ets-2 expression (Figure 2b ). This co-expression of Stromelysin-1 and Ets-1 is in favor of an effective role for endogenous Ets-1 protein in the activation of the Stromelysin-1 promoter under our conditions. Furthermore, it indicates that these cells could be a good model to study molecular transcription mechanisms of pathological processes in which this co-expression has been observed.
Ets-1 is present on the endogenous Stromelysin-1 promoter These results led us to characterize the nature of the proteins bound to the À216/À201 EBS tandem. Electrophoretic mobility shift assays (EMSA) were performed using HIG-82 nuclear extracts and 30-mer 32 P-labeled probes centered on the À216/À201 EBS tandem (Figure 3a) . Incubation of the nuclear extracts with the WT probe ( Figure 3a , lane 1) led to the formation of three complexes (indicated by arrows). Competition with a 400 Â excess of WT or M1M2-unlabeled probe (Figure 3a , lanes 2 and 3) showed that only complex 3 was specific. This was confirmed by the binding of nuclear extract proteins to the M1M2-labeled probe, differing only by the absence of complex 3 (Figure 3a , lane 4). These EMSA were realized with non-stimulated HIG-82 nuclear extracts. Phorbol 12-myristate 13-acetate-or IL-1b-stimulated HIG-82 nuclear extracts led to the same pattern without variation of the relative intensity of the three complexes (data not shown). In order to verify whether Ets-1 is a part of the complex 3, we performed a supershift experiment using an Ets-1-specific antibody (C-20; Santa Cruz, Santa Cruz, CA, USA) ( Figure 3b, lane 4) . The addition of the antibody resulted in the formation of a supershifted band without altering the intensity of the other retarded complexes. Incubation of the antibody with its blocking peptide disrupted the supershifted complex, proving its specificity (Figure 3b , lane 5). Antibodies specific to other ETS proteins shown potentially involved in the activation of the Stromelysin-1 promoter such as Ets-2 (Buttice and Kurkinen, 1993) and Pea-3 (Higashino et al., 1995) were tested, giving negative results (data not shown). The weak intensity of the supershifted band with the Ets-1 antibody might be owing to a low avidity of the antibody for Ets-1 bound to DNA or interacting with other factors in a larger complex. In order to show without any ambiguity that endogenous Ets-1 is able to bind to the EBS tandem, DNA affinity purification using WT or M1M2 biotinylated probes coupled to streptavidin-agarose beads were performed. The presence of Ets-1 was then detected by Western blot experiments, which remove any interference of the DNA-binding or protein partners with Ets-1 detection, with the same Ets-1 antibody that we used for the supershift experiments. Western blot analysis showed that endogenous Ets-1 does not bind significantly to the M1M2 probe ( Figure 3c , lane 2). In contrast, endogenous Ets-1 binds specifically and in large amount to the EBS tandem (Figure 3c, lane 3) . The presence of Ets-1 on the Stromelysin-1 promoter in vivo was then assessed by formaldehyde cross-linking followed by chromatin immunoprecipitation using the C-20 antibody. Polymerase chain reaction (PCR) amplification of the immunoprecipitated DNA with primers flanking the EBS tandem led to the formation of a specific 167 bp band (Figure 3e , lane 5) with a weaker intensity than the one obtained with the input DNA ( Figure 3e, lane 2) . By contrast, no band was amplified by using primers located in the Stromelysin-1 3 0 untranslated region (UTR) (Figure 2e , lane 9), confirming the specific binding of Ets-1 to the endogenous Stromelysin-1 promoter. Although Ets-2 is present in the HIG-82 cells ( Figure 2b ) and in agreement with the results obtained by supershift experiments, no bound Ets-2 to the EBS tandem was detected, either by DNA affinity purification ( Figure 3d, lane 3) or by chromatin immunoprecipitation ( Figure 3e , lane 6). This latter result cannot be owing to the inability of Ets-2 antibody to recognize Ets-2 bound to DNA because this antibody was able to specifically immunoprecipitate overexpressed Ets-2 bound to the Stromelysin-1 promoter transfected in human embryonic kidney (HEK) 293 cells (Figure 3e , compare lanes 12 and 13).
Pharmacological inhibition of Stromelysin-1 and Ets-1 expression by fumagillin The anti-amoebic compound fumagillin and its synthetic analogs are potent antiangiogenic substances able to reduce efficiently tumor growth and invasion. However, their action is not restricted to endothelial cells (Rodriguez-Nieto et al., 2001 ) and some effects have been shown on fibroblasts (Kria et al., 1998) . Interestingly, fumagillin was also reported to inhibit Ets-1 expression induced by vascular endothelial growth factor (VEGF) (Wernert et al., 1999) . In this context, we investigated the effect of fumagillin on Stromelysin-1 and Ets-1 expression in response to IL-1b and PMA in the HIG-82 cell line. Fumagillin was able to inhibit in a dose-dependent manner the induction of Stromelysin-1 by IL-1b and PMA (Figure 4a and b) . At 10 mg/ml, fumagillin totally abrogated Stromelysin-1 induction. However, no effect was detectable on the basal expression of Stromelysin-1. In order to determine whether fumagillin affects the transcriptional control of Stromelysin-1, we performed transactivation assays using the WT or the M1M2 Stromelysin-1 promoter fused to the firefly luciferase coding sequence ( Figure 4c ). According to Stromelysin-1 expression level (Figure 4a and b), fumagillin was able to abrogate the induction of the WT reporter plasmid by PMA, but was without any effect on its basal level. In contrast, M1M2 plasmid was unable to respond to PMA stimulation, 9) or human embryonic kidney (HEK) 293 cells transfected by WT Stromelysin-1 promoter pGL3 construct and pSG5 or pSG5-Ets-2 (lanes 10-13) was formaldehyde cross-linked and subjected to immunoprecipitation using a normal rabbit purified immunoglobulin (Ig) G (Santa-Cruz) (lane 4) or an Ets-1-specific antibody (Santa-Cruz) (lanes 5 and 9) or an Ets-2-specific antibody (Santa-Cruz) (lanes 6, 12 and 13). Immunoprecipitated DNA and input DNA were subjected to a polymerase chain reaction (PCR) for amplification of either Stromelysin-1 promoter (lanes 2-6 and 11-13) or Stromelysin-1 3 0 untranslated region (UTR) (lanes 8 and 9). After 30 cycles of PCR, DNA fragment was resolved on a 2% TBE agarose gel and stained with ethidium bromide.
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We next assessed the implication of Ets-1 in the effect of fumagillin on Stromelysin-1 expression. As for Stromelysin-1, fumagillin dramatically reduced, in a dose-dependent manner, Ets-1 expression induced by IL-1b and PMA (Figure 5a ), suggesting that the inhibition of Stromelysin-1 expression by fumagillin may be owing to the reduction of the Ets-1 protein level. Interestingly, fumagillin was almost without effect on basal expression level ( Figure 5a , lanes 1-4). This result suggests a specific interference with the IL-1b-and PMA-activated signaling pathways resulting in Ets-1 and Stromelysin-1 expression. Transcriptional activation mediated by Ets-1 depends on the phosphorylation of its Thr-38 residue by active phosphorylated Erk-1/-2 (Yang et al., 1996) . Therefore, Erk-1/-2 phosphorylation status was assessed by Western blot. Fumagillin treatment reduced the intensity and duration of the Erk-1/-2 phosphorylation peak owing to PMA (Figure 5b ). However, global Erk-2 amount was not affected, indicating a specific effect of fumagillin on the pathway leading to the Erk-1/-2 phosphorylation, and consecutively to Ets-1 phosphorylation and transcriptional activation. In order to verify it, Erk-2 from cellular extracts of cells treated by PMA alone or PMA and fumagillin was immunoprecipitated and its kinase activity was tested in vitro using recombinant Ets-1 as a substrate. These experiments showed that fumagillin strongly inhibits the phosphorylation of Ets-1 induced by PMA (Figure 5c ), decreasing its potential to transactivate its target promoters, Stromelysin-1 being one of them. Furthermore, Ets-1 is able to transactivate its own promoter (Majerus et al., 1992) . Therefore, fumagillin would be able to inhibit the Stromelysin-1 promoter activation depending on the presence of the EBS tandem by a mechanism involving both the downregulation of Ets-1 expression and Ets-1 activation by phosphorylation through the Erk-1/-2 signaling pathway.
Inhibition of the Stromelysin-1 promoter activity with an Ets-1 dominant-negative mutant The effect of fumagillin on the Stromelysin-1 promoter could result from an indirect mechanism. In order to further investigate the direct implication of Ets-1 into the transcriptional control of Stromelysin-1, we characterized the effect of an Ets-1 dominant-negative mutant (Ets-1dn) on its promoter activity. This was achieved using an expression vector (pcDNA3-Ets-1dn) encoding an N-terminal deletion mutant of Ets-1 lacking its transactivation domain (TAD) (Figure 6a ). This plasmid was used to perform transactivation assays by transient transfection experiments in the presence of either a WT or a M1M2 Stromelysin-1 promoter reporter plasmid. These experiments showed that the Ets-1 dominant-negative mutant strongly reduced the basal transcriptional activity of the WT Stromelysin-1 promoter (17-fold in comparison to the empty pcDNA3-vector) to a level comparable to the basal activity of the M1M2 Stromelysin-1 promoter where the EBS tandem Stromelysin-1 in the presence of fumagillin. Cells were starved with 0.1% serum for 36 h and induced for 24 h with 10 ng/ml interleukin (IL)-1b or 1 ng/ml phorbol 12-myristate 13-acetate (PMA) in the absence or in the presence of 2.5, 5 and 10 mg/ml fumagillin (a). Culture supernatants (50 ml) were dot blotted and the presence of Stromelysin-1 was detected by Western blot (a). Autoradiograms were quantified by densitometry using Genetools software (SYNGENE) (b). (c) Effect of fumagillin on the Stromelysin-1 promoter induction by PMA. WT or M1M2 pGL3 luciferase reporter constructs (100 ng) were transfected into HIG-82 cells at a 50-80% confluence. Cells were starved with 0.1% serum for 36 h before a 24 h induction with 1 ng/ml PMA in the absence or in the presence of 10 mg/ml fumagillin. Luciferase activity is expressed as the pGL3 reporter activity divided by the normalization pRL-null activity.
Results are the average of two representative experiments carried out in triplicates.
Stromelysin-1 promoter regulation by endogenous Ets-1 D Baillat et al is mutated (Figure 6b ). In contrast, the dominantnegative mutant had a weak effect on the basal activity of the M1M2 Stromelysin-1 promoter (Figure 6b ), possibly owing to an indirect inhibition of the other factors involved in the Stromelysin-1 promoter regulation. The Ets-1 dominant-negative mutant also prevented PMA-induced activation of the WT Stromelysin-1 promoter, bringing down its transcriptional activity to the same value that the ones obtained with the control vector and the M1M2 Stromelysin-1 promoter (Figure 6c ). In contrast, no effect was observed on the PMA induction of the M1M2 Stromelysin-1 promoter activity in the presence of Ets-1dn (Figure 6c ). Furthermore, Ets-1dn was unable to prevent PMAinduced activation of an activator protein-1 (AP-1)-dependent reporter plasmid, p(7x) TRE-Luc, another PMAinducible (but Ets-1 independent) promoter construct or induced with 10 ng/ml interleukin (IL)-1b (lanes 5-8) or 1 ng/ml phorbol 12-myristate 13-acetate (PMA) (lanes 9-12) with various amounts (0, 2.5, 5 and 10 mg/ml) of fumagillin were subjected to a 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), blotted and analysed by Western blot for the presence of Ets-1. A Ponceau staining was used as loading control.
(b) Effect of fumagillin on Erk-1/-2 activation by PMA. Starved HIG-82 cells were treated with 1 ng/ml PMA in the presence or the absence of 10 mg/ml fumagillin. Cells were lysed in Laemmli buffer at different times (0, 5, 15, 30, 60, 120 min) . Total cell lysates were submitted to an SDS-PAGE and subsequent Western blot analysis for the presence of p-Erk-1/-2 or Erk-2. (c) Effect of fumagillin on the phosphorylation state of Ets-1. Cells were starved for 36 h and induced with 1 ng/ml PMA in the absence or in the presence of 10 mg/ml fumagillin. Total cell lysates were immunoprecipitated with an Erk-2 C-14 polyclonal antibody (Santa Cruz). Each immunoprecipitate was used for in vitro kinase assay in the presence of g-[
32
P]ATP and recombinant human Ets-1 protein used as a substrate. Kinase reactions were stopped by the addition of 10 ml of 5 Â Laemmli sample buffer. The phosphorylated form of Ets-1 was resolved by a 10% SDS-PAGE. Figure 6c ). These results emphasize the direct role of endogenous Ets-1 through its binding to the EBS tandem in the activation of the Stromelysin-1 promoter. Endogenous Ets-1 protein level directly affects Stromelysin-1 promoter activity and protein expression We investigated the effect of the genetic inactivation of Ets-1 using short interfering RNA (siRNA) on the promoter activity and expression of Stromelysin-1. As no rabbit ets-1 sequence was available in the data banks, we determined its complete coding sequence. It was submitted to the Genbank database and is available under Accession number AY561276 (see Materials and methods). Two 19 bp sequences (named A2 and B1) were chosen for our siRNA experiments using transiently transfected pSUPER vectors (Figure 7a ). These A2 and B1 sequences specifically target the region corresponding to the exon VII of the human ets-1 gene and should result in the specific inhibition of the p51 Ets-1 full-length isoform. We first verified that these constructs were able to reduce endogenous Ets-1 protein level in comparison to a GFP siRNA expressing control vector. In HIG-82 cells, pSUPER-A2 and pSUPER-B1 constructs induced a decrease in endogenous Ets-1 expression starting 48 h after transfection (Figure 7b) . After 72 h, a 62-65% decrease was measured for a determined transfection efficiency of 60-70%. No knockdown of Ets-2, another Ets protein from the same group and very close phylogenetically to Ets-1, was observed, confirming the specificity of our siRNA experiments (Figure 7b ). The impact of this reduction on the Stromelysin-1 promoter activity was evaluated by co-transfection of pSUPER vectors with either the WT or the M1M2 Stromelysin-1 promoter reporter plasmid. These experiments showed that the inhibition of Ets-1 by siRNA reduced the WT Stromelysin-1 promoter activity by more than 60% (Figure 7c ), but had no effect on the activity of the M1M2 promoter ( Figure 7d) . Next, we determined the effect of siRNA-mediated Ets-1 knockdown on Stromelysin-1 expression. Given the weakness of basal Stromelysin-1 expression in HIG-82 cells, these experiments were performed under PMA induction. As expected, pSUPER-A2 and pSUPER-B1 transient transfections were able to downregulate Ets-1 expression in response to PMA in comparison to the control vector (Figure 7e) . Furthermore, this decrease of the Ets-1 protein level fully correlated with the reduction of Stromelysin-1 expression level (Figure 7e ). These results clearly demonstrated the importance and the implication of the endogenous Ets-1 protein in the activation of Stromelysin-1 expression in HIG-82 cells. co-expression of Ets-1 and Stromelysin-1 during invasive pathologies such as rheumatoid arthritis (Sun and Yokota, 2001) or tumor growth (Calmels et al., 1995; Barrett et al., 2002) , and (iii) a decrease of Stromelysin-1 expression using Ets-1 antisense nucleotides (Ozaki et al., 2003; Rothhammer et al., 2004) . Nevertheless, no study has been performed to show a direct link between the EBS palindrome, endogenously expressed Ets-1 and Stromelysin-1 expression using the same cellular model. We previously showed that this EBS palindrome is able to induce, through protein-protein interactions, a mutual autoinhibition counteracting of each molecule. This mechanism leads to the formation of a Ets-1-DNA-Ets-1 ternary complex crucial for optimal transactivation of the Stromelysin-1 promoter (Baillat et al., 2002) .
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Discussion
Our present work documents, from a molecular to a cellular point of view, the importance of the palindrome and the implication of the endogenously expressed Ets-1 in the expression of Stromelysin-1 (Figure 8 ). This study was performed in immortalized synovial fibroblastic cells (HIG-82) that represent a good model to study transcription mechanisms of pathological processes, such as rheumatoid arthritis and tumor growth and invasion, in which the coexpression of both proteins has been observed. Thus, the EBS palindrome appears to be a main regulator element of the Stromelysin-1 promoter and the presence of endogenous Ets-1, but not Ets-2 in our cellular context, bound to this element leads to a transactivation of the promoter and to an increase in Stromelysin-1 expression. It is noteworthy that in another cell type and under other conditions, Ets-2, but not Ets-1, regulates Stromelysin-1 expression. Indeed, macrophages from knock-in mice deficient for mitogen-activated protein (MAP) kinase phosphorylation of Ets-2, are deficient for Stromelysin-1 expression in response to colony-stimulating factor-1 (CSF-1) alone or to the combination of interferon-g (IFN-g) and lypopolysaccharide (LPS) (Man et al., 2003) . In addition, mice with a targeted deletion of the Ets-2 DNAbinding domain show some tissue specificity in the effects of Ets-2 on the expression of Stromelysin-1 (Yamamoto et al., 1998) . Unfortunately, no study of the expression of Stromelysin-1 was performed using Ets-1 À/À mice. Our results show that the greater is the quantity of Ets-1, the higher is Stromelysin-1 expression. Surprisingly, we did not find any difference for Ets-1 binding to the EBS palindrome in the absence or presence of PMA during EMSA. One can argue that transactivation of the Stromelysin-1 promoter by Ets-1 is merely owing to its activation by signaling pathways rather than by an enhanced binding to the EBS palindrome. However, on the one hand, it was shown that induction of Stromelysin-1 by PMA needs a new protein synthesis (Frisch et al., 1987) , and on the other hand, the effect of the decrease of Ets-1 amount by siRNA points out that Ets-1 quantity is important for Stromelysin-1 expression. In addition, it is known that Ets-1, as the other Ets proteins, does not regulate its target promoters on its Stromelysin-1 promoter regulation by endogenous Ets-1 D Baillat et al own, but in association with co-factors (Graves and Petersen, 1998) . It is admitted that the AP-1 pathway is important for PMA induction, but other factors appear required (Gaire et al., 1996) . Given the presence of a downstream AP-1-like site close to the EBS palindrome (Crawford and Matrisian, 1996) , which is not present in the double-stranded synthetic oligonucleotides used for electrophoretic mobility shift assay (EMSA), we can HIG-82 cells were transfected with 500 ng pSUPER (GFP, A2 or B1) construct. Cells were starved in medium with 0.1% serum for 36 h before a 24 h induction with 1 ng/ml PMA. Cells were lysed in Laemmli buffer. Total cell extracts were submitted to SDS-PAGE and Western blot analysis for the presence of Ets-1, Ets-2, MMP-3 and TAFIIp32. Autoradiograms were quantified by densitometry using Genetools software (SYNGENE).
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speculate that an AP-1 complex could increase Ets-1 binding to the EBS palindrome during PMA induction in the context of the full-length promoter.
In the course of this study, we used the fungal antiangiogenic compound fumagillin because of its previously reported ability to downregulate the Ets-1 expression (Wernert et al., 1999 ). The precise mechanism of action of this drug and its derivatives remains unclear. They have been shown to inhibit both endothelial and non-endothelial cells (Ingber et al., 1990; Wang et al., 2000; Rodriguez-Nieto et al., 2001) . Their only known target is the methionine aminopeptidase-2 (MetAP-2), also named eukaryotic initiation factor-2-associated glycoprotein, p67 (Sin et al., 1997) . However, the link between covalent MetAP-2 inhibition and the angiostatic effect is not clear yet. MetAP-2 is responsible for the removal of N-terminal methionine residues from specific proteins (Lowther and Matthews, 2000) , which is a pre-requisite for a variety of biological processes, such as activity, subcellular localization and protein stability. Reducing the expression of this enzyme was able to induce apoptosis in pulmonary cancer cells (Catalano et al., 2001) , whereas its pharmacological inhibition by fumagillin or related compounds usually inhibits cell proliferation in various cell types (Rodriguez-Nieto et al., 2001) owing to a blockage in the G1 phase of the cell cycle (Zhang et al., 2000) . Our results confirm the downregulation of neo-synthesized Ets-1 expression by fumagillin and show a concomitant reduced amount of Stromelysin-1 (Figure 8 ). Interestingly, a recent study showed that fumagillin binding to MetAP-2 was able to increase MetAP-2 stability in mouse myoblasts. The increased levels of MetAP-2 resulted in inhibition of phosphorylation of extracellular signal-regulated kinases 1 and 2: Erk-1/-2 (Datta et al., 2004) . In our case, under PMA treatment, our experimental data also reveal an effect of this drug on the activation state of mitogen-activated protein (MAP) kinase Erk-1/-2, resulting in the inhibition of its phosphorylation and therefore of its kinase activity in general. Indeed, a reduced intensity and duration of the Erk-1/-2 phosphorylation peak owing to PMA (Figure 5b) were observed, resulting in a downregulation of the activation status of Ets-1 by phosphorylation. Our results confirm that fumagillin might antagonize mitogenic signaling pathways, providing new hints to understand its action. Ets-1 being one of the terminal transcriptional effectors of the Ras-Raf-MAP kinase pathway, which expression is increased in response to the activation of VEGF receptors, is an important factor of angiogenesis (Iwasaka et al., 1996) . Therefore, the antiangiogenic effect of fumagillin could be a consequence of the downregulation of both Ets-1 expression and Ets-1 activation by phosphorylation through the Erk-1/-2 signaling pathway (Figure 8 ). Indeed, this dual effect of fumagillin on Ets-1 is able to totally abrogate Stromelysin-1 induction, an MMP also involved in angiogenesis (Sato et al., 2000) . It is noteworthy that PPI-2458, a member of the fumagillin class of compounds, potently inhibits the proliferation of human fibroblast-like synoviocytes derived from rheumatoid arthritis patients and displays a significant in vivo activity in a rat model of rheumatoid arthritis. This feature supports the potential application of PPI-2458 as a drug for the treatment of rheumatoid arthritis, disorder in which an induced co-expression of Ets-1 and Stromelysin-1 is observed linked to a pathological neovascularization (Bernier et al., 2004) . The induction of various MMPs is dependent on MAP kinase activation and Ets factors . If such results obtained with Stromelysin-1 could be extended to other MMPs, this inhibitory activity could be added to the mechanism of action of fumagillin and its derivatives to all diseases where pathological angiogenesis occurs.
The inhibition of the Stromelysin-1 promoter activity by both an Ets-1dn and genetic inactivation of Ets-1 using siRNA clearly shows the implication of Ets-1 in the transcriptional regulation of the Stromelysin-1 through the EBS palindrome and supports our results obtained with fumagillin ( Figure 8 ). In addition, under PMA induction, the siRNA-mediated Ets-1 knockdown leads as predicted to a significant decrease in the protein level of Stromelysin-1. Importantly, as no knockdown of endogenous Ets-2 was detected, this indicates the major role, in this system, of endogenous Ets-1 in the decrease of the Stromelysin-1 protein level observed. A recent study, using MDA-MB-231 breast cancer cells showed no reduction of messenger RNA level of Stromelysin-1 when endogenous PKCa and Ets-1 expression was Stromelysin-1 promoter regulation by endogenous Ets-1 D Baillat et al suppressed by RNA interference (Vetter et al., 2005) . Interestingly, in this cellular context, the authors show, on the one hand, that calcium/calmodulin-dependent kinase II (CaMKII) is involved in PKCa-dependent regulation of Ets-1 expression, and on the other hand that Ets-1-regulating kinases Erk-1/-2 are not implicated in this process. Our work using fibroblastic HIG-82 cells indicates that, in these cells, the PMA-induced Stromelysin-1 expression follows rather the calcium independent Ras-Raf-MAP kinase pathway to activate Ets-1 by phosphorylation at its N-terminus (Thr-38). This finding is in agreement with the major role of Ets-1 as an activator of Stromelysin-1 expression through its binding to the palindromic head-to-head EBS present in the promoter. Indeed, CaMKII phosphorylation of Ets-1 on residues Ser-251, Ser-270, Ser-273, Ser-282 and Ser-285 was reported to negatively regulate Ets-1 DNA binding in vitro and in vivo by reinforcing autoinhibition (Pufall et al., 2005) . We previously demonstrated that reinforcing autoinhibition through CaMKII phosphorylation reduced dramatically the cooperative binding of Ets-1 to the EBS palindrome preventing the formation of the ternary Ets-1-DNA-Ets-1 complex, important for a full transactivation of the Stromelysin-1 promoter (Baillat et al., 2002) . A recent work using mutant K-ras stably transfected human adrenocortical cells reinforces this view. Indeed, the authors reported that the activation of Ets-1 through its phosphorylation at Thr-38 by Erk-1/-2 upregulates the expression of urokinase-type plasminogen activator, Stromelysin-1 and Prolactin (Chen et al., 2005) . On the contrary, they found that CaMKII phosphorylation of Ets-1 brings it to an inactivated state, which in turn leads to an upregulation of other downstream genes and inhibit the downstream carcinogenic mechanism of Ets-1. Taken together, our results provide a molecular insight for previous reports relating the co-expression of Ets-1 and Stromelysin-1 in the stroma of invasive tumor (Wernert et al., 1994) . We demonstrate for the first time the implication of endogenous Ets-1 as an activator of Stromelysin-1 through its binding to the EBS palindrome. Our work also suggests a potential role for Ets-1 in the establishment of the stromal alterations associated with the tumor-promoting activity of Stromelysin-1 demonstrated in vivo in a transgenic model . Apart from cancer, these results, obtained in synovial fibroblastic cells, establish a clear link between Ets-1 and Stromelysin-1 in invasive rheumatoid diseases suggested in recent studies (Redlich et al., 2001; Sun and Yokota, 2001 ) where overexpression of both proteins is associated with mechanical stimulation and inflammation.
Materials and methods
Cell culture HIG-82 rabbit synovial fibroblasts were obtained commercially (ATCC, Manassas, VA, USA; CRL-1832) and routinely cultured in F-12 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 50 mg/ml gentamycin. All experiments were carried out between 7 and 14 passages. For induction experiments, 50-70% confluent cells were starved for 36 h in F-12 medium with 0.1% fetal bovine serum. The medium was then replaced by the same fresh medium supplemented with 1 ng/ml PMA (Sigma, St Louis, MO, USA) or 10 ng/ml IL-1b (Calbiochem, Darmstadt, Germany) followed by a 24 h incubation. When the activity of fumagillin was assessed, medium containing 10 mg/ml fumagillin (Sigma) was added 1 h before the addition of PMA. HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 50 mg/ml gentamycin.
Nuclear extracts
Nuclear extracts were prepared according to (Andrews and Faller, 1991) .
Isolation of rabbit ets-1 cDNA We used the reverse transcription (RT)-PCR technique to isolate the ets-1 cDNA from HIG-82 cells. We first determined the sequences of the 5 0 -and 3 0 -terminal regions of rabbit ets-1 cDNA. The rapid amplification of cDNA ends (RACE) method (Frohman et al., 1988) 
Vector construction
The construction of Stromelysin-1 promoter pGL3 reporter plasmids was described previously (Baillat et al., 2002) . To construct the pcDNA3-Ets-1dn vector, the cDNA sequence encoding the mouse DN323 Ets-1 mutant, obtained by PCR amplification of mouse ets-1 cDNA (Chen, 1990) 0 -GATCTGATCCCCAGGACAAGCCTGTC ATTCCTTCAAGAGAGGAATGACAGGCTTGTCCTTTTT TGGAAAA-3 0 , respectively, into a pSUPER vector (Oligoengine, Seattle, WA, USA) previously digested by BglII and HindIII restriction endonucleases. These oligonucleotides were generated using the OligoEngine Workstation software (OligoEngine). Sequences belonging to the rabbit ets-1 gene are indicated in bold.
Western Blot analysis
For Stromelysin-1 analysis, 50 ml of culture supernatant was either subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to an Immobilont-P membrane (Millipore, Billerica, MA, USA) or diluted in 900 ml phosphate-buffered saline (PBS) buffer (Gibco) and blotted on an Immobilont-P membrane using a Minifold I apparatus (Schleicher & Schuell, Brentford, UK). For cellular protein detection, 30 mg of cell lysate total protein were subjected to SDS-PAGE and transferred to an Immobilont-P membrane. Stromelysin-1 was detected using an MAB3312 monoclonal antibody (Chemicon, Temecula, CA, USA). Ets-1 was detected with a monoclonal Ets-1 antibody (Transduction Laboratories, San Jose, CA, USA) or Ets-1 C-20 polyclonal antibody (Santa Cruz), Ets-2 with a C-20 polyclonal antibody (Santa Cruz), TAFIIp32 with an N-16 polyclonal antibody (Santa Cruz), Erk proteins with a Erk-2 C-14 polyclonal (Santa Cruz) and p-Erk with an E-4 monoclonal antibody (Santa Cruz). Autoradiograms were quantified by densitometry using Genetools software (SYNGENE, Cambridge, UK).
Electrophoretic mobility shift assay Double-stranded synthetic oligonucleotides corresponding to the WT and M1M2 mutants of the human Stromelysin-1 (À223/À194) promoter region were end-labeled using T4 polynucleotide kinase and [g-32 P]ATP, and were subsequently purified by electrophoresis on a 20% polyacrylamide gel in tris-borate ethylene-diaminetetraacetic acid (TBE) buffer (90 mM) Tris-borate, 1 mM ethylenediaminetetraacetic acid (EDTA). Nuclear extracts (2.5 mg) were incubated with 0.5 ng of probe in 20 ml binding reaction buffer (20 mM Tris, pH 7.9, 80 mM NaCl, 1 mM EDTA, 2 mM dithiothreitol (DTT)), 50 mg/ ml poly[dI-dC]poly[dI-dC] (Pharmacia, Piscataway, NJ, USA; 10% glycerol) for 30 min on ice. Complexes formed were resolved on a 5% polyacrylamide (acrylamide/bisacrylamide 29:1; Euromedex, Souffelweyersheim, France) non-denaturing gel in 0.25 Â TBE buffer at 41C. Gels were dried and autoradiographied at -801C. For supershift experiments, 400 ng of Ets-1 C-20 polyclonal antibodies (Santa Cruz) were added to the reaction, which was incubated 15 min at 251C before addition of the radiolabeled probe.
DNA affinity purification Nuclear extracts (50 mg) were incubated for 30 min at 41C in 500 ml binding reaction buffer (see Electrophoretic mobility shift assay) with 2 mg of double-stranded oligonucleotides biotinylated at the 5 0 -end of their upper strand and corresponding to the WT or M1M2 mutants of the human Stromelysin-1 (À223/À194) promoter region. Streptavidin Sepharoset (20 ml) (Amersham Bioscience, Piscataway, NJ, USA) was then added to the reaction mixture for 30 min. Beads were washed three times with binding reaction buffer and eluted by the addition of 50 ml of SDS-PAGE loading buffer (2% SDS, 5% 2-mercaptoethanol, 50 mM Tris-HCl, pH 6.8, 0.1% bromophenol blue, 10% glycerol) and a subsequent 2 min boiling. The presence of Ets-1 and Ets-2 was detected by Western blot analysis.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were carried out mainly according to Boyd et al. (1998) . Briefly, 10 7 cells were used for each tested condition. Sonicated chromatin was diluted 10-fold in 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris, pH 8.1, 167 mM NaCl. Immunoprecipitation were performed overnight at 41C using 1 mg of Ets-1 C-20 antibody (Santa Cruz) or 1 mg of Ets-2 C-20 antibody (Santa Cruz) or 1 mg of purified normal rabbit immunoglobulin (Ig) G (Santa Cruz) and EZviewt Red Protein A Gel (Sigma) as an affinity matrix. Before elution of immune complexes, beads were washed, once with 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 20 mM Tris, pH 8.1, 150 mM NaCl, once with 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 20 mM Tris, pH 8.1, 500 mM NaCl, once with 0.25 M LiCl, 1% NP40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris, pH 8.1 and twice with 10 mM Tris pH 8, 1 mM EDTA. DNA was resuspended in a final volume of 100 ml H 2 O. Polymerase chain reactions were performed under 30 ml volume with 3 ml of immunoprecipitate or 1/100 e diluted input DNA as a template in the presence of 1.25 U AmpliTaq Gold (Perkin-Elmer, Welleslay, MA, USA) and 100 mM dNTP using 50 ng 5 0 -CCCAGTTTTCTCTTTTGCCA-3 0 and 5 0 -TTGC CTTCATCCATACGACA-3 0 oligonucleotides (for endogenous Stromelysin-1 promoter amplification), or 50 ng 5 0 -TCC AGTTTTCTCCTCTACCA-3 0 and 5 0 -TTGCTTTCATCC AAATGGCA-3 0 oligonucleotides (for WT Stromelysin-1 promoter pGL3 amplification), or 50 ng 5 0 -TGAAGTGGCT-CATTTTCTCC-3 0 and 5 0 -GTCTCGTGGAACTCCCTTC-3 0 oligonucleotides (for Stromelysin-1 3 0 UTR amplification). Reaction was cycled 30 times with 30 s denaturation at 961C, 30 s hybridization at 551C and 30 s elongation at 721C using a GeneAmp 2400 PCR system (Applied Bioscience). Polymerase chain reaction products were analysed on a 2% agarose gel run in 0.5 Â TBE buffer and stained with ethidium bromide.
In vivo mitogen-activated protein kinase assay In vivo MAP kinase assays were performed according to (Paumelle et al., 2002) . Cells (10 6 ) treated 30 min with PMA (1 ng/ml) in the absence or presence of fumagillin (10 mg/ml) (see Cell culture) were washed twice with ice-cold PBS and suspended in lysis buffer (25 mM HEPES, pH 7.5, 100 mM NaCl, 1.5 mM MgCl 2 , 0.5 mM ethyleneglycol tetraacetate, 0.25 mM EDTA, 0.1% NP40, 10 mM NaF, 20 mM b-glycerophosphate, 1 mM Na 3 VO 4 , protease inhibitor cocktail (Completet, Roche, Basel, Switzerland)). Lysates were clarified by centrifugation at 20 000 g and 41C. Protein concentration was determined by Bio-Rad protein assay. Total protein (200 mg) in cell lysates were incubated overnight with 0.6 mg of an Erk-2 C-14 polyclonal antibody (Santa Cruz) at 41C on a revolving wheel, and then incubated with 20 ml of EZviewt Red Protein A Gel (Sigma) for 1 h at 41C. Immune complexes were washed four times with ice-cold lysis buffer, and once with kinase buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 12.5 mM MgCl 2 , 1 mM DTT, 1 mM Na 3 VO 4 , 1 mM phenylmethyl sulfonyl). Each immunoprecipitate was incubated for 30 min at 301C with 40 ml of kinase buffer containing 20 mM ATP, 3.75 mM [g-32 P]ATP (5 mCi) and 1 mg of recombinant human Ets-1 (Baillat et al., 2002) as a substrate. Kinase reactions were stopped by the addition of 10 ml of 5 Â Laemmli sample buffer (Laemmli, 1970) . The phosphorylated form of Ets-1 was resolved by 10% SDS-PAGE. The gel was washed three times with a destaining solution (50% methanol, 7.5% acetic acid), dried and autoradiographed at À801C.
Transient transfection and reporter gene assay
Transfections of HIG-82 cells were performed by incubating 100 ng of each Stromelysin-1 promoter pGL3 reporter plasmid or an AP-1-dependent reporter plasmid (p(7 Â )TRE-Luc; Stratagene, La Jolla, CA, USA), 12.5 ng of normalization vector pRL-null (Promega, Madison, WI, USA) and sufficient amount of pUC19 to reach 500 ng of DNA with Exgen 500 Transfection Reagent according to the manufacturer's instructions (Euromedex, Souffelweyersheim, France). For Ets-1dn and RNA interference experiments, pUC19 was replaced by pcDNA3-Ets-1dn or pSUPER constructs. Transfections of HEK293 cells were performed by incubating 3 mg of pSG5 (Stratagene) or pSG5-Ets-2 vector (Wakiya et al., 1996) and 3 mg of WT Stromelysin-1 promoter pGL3 plasmid with Exgen 500 Transfection Reagent according to the manufacturer's instructions (Euromedex). For reporter gene assay, cells were harvested 48 h after transfection with 300 ml of cell lysis buffer (1% Triton X-100, 25 mM glycylglycine, pH 7.8, 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT) and each supernatant was sequentially tested for firefly and Renilla luciferase activity (Dual-Luciferase s Reporter Assay System, Promega) using a Lumat LB 9501 (Berthold, Bad Wildbad, Germany).
